UK Launch of LVOne Stroke Triage Test by UpFront Diagnostics
POLB 001 cancer immunotherapy-induced CRS patent granted in Canada
Further strengthening of Poolbeg’s global intellectual property portfolio
Why 2026 could be a defining year for Poolbeg Pharma
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial
Physiomics plc (AIM: PYC) Strategy Update
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that the newly
Abingdon Health updates on collaboration with 4TEEN4 Pharmaceuticals
Abingdon Health plc (AIM: ABDX) has provided an update on its partnership with 4TEEN4 Pharmaceuticals GmbH, focused on the co-development of a companion diagnostic for a potentially life-saving shock therapy.
Avacta Therapeutics (AIM: AVCT) Pre|CISION® payload release vs approved ADCs
Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
Physiomics plc (AIM: PYC) shareholders approve board shake-up
Physiomics plc has confirmed a significant board overhaul following the successful passage of all resolutions at its recent general meeting.
Zak Mir talks to Dr Jim Millen, Non-Executive Chairman, Physiomics PLC
Zak Mir talks to Dr Jim Millen, Non-Executive Chairman, Physiomics, regarding recent progress at the mathematical modelling, data science and biostatistics company, and issues regarding the forthcoming requisitioned meeting.
Poolbeg Pharma is stepping up partnering discussions with multiple pharma groups
Poolbeg Pharma PLC (AIM: POLB) is stepping up partnering discussions with multiple pharma groups as it approaches a series of near-term clinical catalysts that could unlock a deal.
Avacta Therapeutics (AIM: AVCT) Avacta data AACR underline AVA6103 profile
Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with
Poolbeg Pharma CEO speaks on BioHub podcast in London
In this episode of The BioHub Podcast, Max sits down in person in London with Jeremy Skillington, CEO of Poolbeg Pharma.
Poolbeg Pharma receives UK clearance to begin cancer immunotherapy trial
Poolbeg Pharma plc (AIM: POLB) has received Clinical Trial Authorisation (CTA) from the Medicines and Healthcare products Regulatory Agency for its POLB 001 TOPICAL trial, marking a key regulatory milestone